ZLAB

News Zai Lab announces departure of President and COO Josh Smiley

11d ago

SEC filing ZLAB Announces Josh Smiley's Departure as President & COO, Samantha Du Assumes Responsibilities

11d ago

News Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback

14d ago

Insider trade Sale by Du Ying (Chairperson & CEO)

17d ago

Insider trade Sale by Edmondson Frazor Titus III (Chief Legal Officer)

17d ago

News Zai Lab expects Zoci Phase III enrollment completion in first half of 2027, while targeting first FDA BLA in late 2027

25d ago

Insider trade Sale by Ying Du (Chairperson & CEO)

54d ago

Insider trade Sale by Frazor Titus Edmondson III (Chief Legal Officer)

54d ago

Insider trade Sale by Joshua L Smiley (President and Chief Operating Officer)

54d ago

Insider trade Sale by Rafael Amado (President, Head of Global Oncology Research and Development)

54d ago

Insider trade Sale by Yajing Chen (Chief Financial Officer)

54d ago

Insider trade Purchase by Richard Gaynor

74d ago

Insider trade Sale by Joshua L Smiley (President and Chief Operating Officer)

77d ago

Insider trade Sale by Frazor Titus Edmondson III (Chief Legal Officer)

77d ago

Insider trade Sale by Yajing Chen (Chief Financial Officer)

77d ago

Insider trade Sale by Rafael Amado (President, Head of Global Oncology Research and Development)

77d ago

Insider trade Sale by Ying Du (Chairperson & CEO)

81d ago

Insider trade Sale by Ying Du (Chairperson & CEO)

83d ago

Insider trade Sale by Frazor Titus Edmondson III (Chief Legal Officer)

87d ago

Insider trade Sale by Ying Du (Chairperson & CEO)

87d ago

Insider trade Sale by Rafael Amado (President, Head of Global Oncology Research and Development)

88d ago

News Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028

95d ago

News $207B Market Shift: The Race for Fast Track Approval in Oncology

117d ago

News NovoCure projects $13M monthly revenue hit as Medicare revokes billing privileges

117d ago

News ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025

117d ago